Table 2.
Annualized event rates (percent) and hazard ratios for the composite outcome of cardiovascular and kidney events or all-cause mortality in ASTRAL trial participants undergoing renal revascularization alongside standard of care, versus those only managed with medical standard of care. Findings are adjusted for baseline age, gender, and kidney function, and displayed according to subgroups of clinical phenotypes and stenosis severity.
| Population | N |
Any event (n, %) |
Annualized event rate (any event)a |
HR (95% CI) | P | P (interaction) | |||
|---|---|---|---|---|---|---|---|---|---|
| Medical | Revasc | Medical | Revasc | Medical | Revasc | ||||
| ASTRAL bilateral severe stenosis ≥ 70% | |||||||||
| All patients | 106 | 108 | 70 (66) | 62 (57) | 25.9 | 19.7 | 0.70 (0.50, 0.99) | 0.048 | 0.801 |
| High risk phenotypes | 83 | 85 | 59 (71) | 52 (61) | 29.8 | 22.1 | 0.70 (0.48, 1.03) | 0.07 | - |
| Non-high risk | 23 | 23 | 11 (47) | 11 (47) | 15.2 | 13.6 | 0.50 (0.20, 1.28) | 0.15 | - |
| ASTRAL bilateral moderate or severe stenosis (≥50%) | |||||||||
| All patients | 202 | 188 | 129 (63) | 112 (59) | 24.6 | 21.0 | 0.85 (0.66, 1.10) | 0.218 | 0.116 |
| High risk phenotypes | 161 | 145 | 108 (67) | 96 (66) | 27.1 | 25.3 | 0.91 (0.69, 1.21) | 0.522 | - |
| Non-high risk | 41 | 43 | 21 (51) | 16 (37) | 16.9 | 10.4 | 0.58 (0.30, 1.15) | 0.121 | - |
| ASTRAL unilateral severe stenosis ≥70% with any disease <70% in contralateral kidney | |||||||||
| All patients | 212 | 212 | 118 (55) | 117 (55) | 18.2 | 19.5 | 1.06 (0.82, 1.37) | 0.663 | 0.168 |
| High risk phenotypes | 160 | 138 | 100 (62) | 85 (61) | 21.1 | 24.0 | 1.09 (0.81, 1.46) | 0.568 | - |
| Non-high risk | 52 | 74 | 18 (34) | 32 (43) | 10.3 | 13.1 | 1.27 (0.70, 2.03) | 0.44 | - |
Abbreviations: HR, hazard ratio.
a
% per year.